Comparing effectiveness and safety of adalimumab and infliximab in biologic-naive patients with Crohn's disease -a population-based Danish real life cohort study

Trial Profile

Comparing effectiveness and safety of adalimumab and infliximab in biologic-naive patients with Crohn's disease -a population-based Danish real life cohort study

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs Adalimumab (Primary) ; Infliximab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Jan 2018 New trial record
    • 14 Dec 2017 Primary endpoint has not been met. (Effectiveness outcomes) as per results published in the Alimentary Pharmacology and Therapeutics
    • 14 Dec 2017 Results published in the Alimentary Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top